NHS to get revolutionary new ovarian cancer drug
A "game-changing" drug for women with ovarian cancer has been approved as a first treatment on the NHS.
Lynparza (olaparib) is being made available through the Cancer Drugs Fund to help women with a genetic form of ovarian cancer - a disease which is notoriously deadly and difficult to treat.
The drug has been shown to extend lives by more than doubling the number of patients whose cancer is prevented from getting worse, and could offer a cure for some women.
The medicine is for those newly-diagnosed with ovarian cancer that has spread, who have the inherited BRCA gene mutation which is responsible for about one in five ovarian cancers.
Yesterday Annwen Jones, chief executive of Target Ovarian Cancer, said: "For the first time women with a BRCA mutation will be able to access this game-changing new generation of ovarian cancer drugs from their first round of treatment."